Last edition
News about "IO therapy"
Innovent Doses First Patient in Pivotal IBI363/TAK-928 CRC Study
Innovent has dosed the first patient in its pivotal IBI363/TAK-928 study, advancing next-generation immunotherapy for colorectal cancer.
IO Therapy | 06/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members